Core Viewpoint - The company Baoren Medical reported a significant increase in both revenue and net profit for the first half of the year, indicating strong financial performance and growth potential [1]. Financial Performance - The company's operating revenue for the first half of the year reached 248,028,217.88 yuan, representing a year-on-year increase of 30.07% [1]. - The net profit attributable to shareholders of the listed company was 71,400,619.61 yuan, showing a substantial year-on-year increase of 102.9% [1].

Group 1 - The core viewpoint of the report highlights the financial performance of Beijing Balancemed Medical Technology Co., Ltd. for the first half of 2025, showing significant growth in revenue and profit metrics [1][2]. - Total assets at the end of the reporting period amounted to approximately 1.45 billion RMB, reflecting a 1.62% increase compared to the end of the previous year [2]. - The company's operating income reached approximately 248 million RMB, representing a 30.07% increase year-on-year [2]. - The total profit for the period was approximately 76.4 million RMB, marking a substantial increase of 120.73% compared to the same period last year [2]. - The net profit attributable to shareholders of the listed company was approximately 61.4 million RMB, an increase of 88.55% year-on-year [2]. Group 2 - The report indicates that the company has a total of 3,426 shareholders as of the reporting period [3]. - The top ten shareholders include individuals and entities with varying ownership percentages, with the largest shareholder holding 61.21% of the shares [3][4]. - The report does not indicate any significant changes in the company's operational situation or any major events that would impact future operations [5].

Meeting Details - The third meeting of the supervisory board of Beijing Bairen Medical Technology Co., Ltd. was held on August 27, 2025, in a combined format of on-site and remote voting [1] - The meeting was convened by the chairwoman Wang Donghui, with all three supervisors present, ensuring compliance with relevant laws and the company's articles of association [1] Supervisory Board Resolutions - The supervisory board unanimously approved the proposal regarding the company's 2025 semi-annual report and its summary, confirming that the report's preparation and review procedures comply with legal regulations and internal control systems [2] - The content and format of the 2025 semi-annual report meet the requirements set by the China Securities Regulatory Commission and the Shanghai Stock Exchange, reflecting the company's true, accurate, and complete status [2] - The board also approved the proposal to abolish the supervisory board, transferring its powers to the audit committee of the board of directors, with the relevant rules being nullified [2]

Core Viewpoint - Beijing Balancemed Medical Technology Co., Ltd. plans to hold a semi-annual performance briefing on September 4, 2025, to discuss its 2025 semi-annual report and address investor concerns [1][2]. Group 1: Meeting Details - The performance briefing will take place on September 4, 2025, from 10:00 AM to 11:00 AM [1][3]. - The meeting will be held at the Shanghai Stock Exchange's "SSE Roadshow Center" and will be conducted in an interactive online format [1][3]. - Participants will include the company's Chairman and General Manager, Jin Lei, along with other key executives [1]. Group 2: Investor Participation - Investors can participate online through the SSE Roadshow Center during the scheduled time [2][3]. - Questions can be submitted by investors from August 28, 2025, to September 3, 2025, before 4:00 PM, either through the SSE Roadshow Center or via the company's email [2][3]. - The company will address commonly asked questions during the briefing [2][3]. Group 3: Contact Information - The contact person for inquiries is Wang Lili, reachable at phone number 010-60735931 or via email at ir@balancemed.cn [2].

Core Points - The internal audit system of Beijing Baijun Medical Technology Co., Ltd. aims to standardize internal audit work, clarify responsibilities, ensure audit quality, and enhance economic efficiency [1][2] - The internal audit is defined as an independent and objective evaluation of financial activities, internal controls, and risk management to promote governance and achieve organizational goals [1][2] - The internal audit's objectives include improving internal controls, managing costs effectively, enhancing operational management, mitigating operational risks, and increasing company value [1][2] Chapter Summaries Chapter 1: General Principles - The internal audit system is established to comply with relevant laws and regulations, ensuring the integrity of financial reporting and internal controls [1][2] - Internal controls are defined as processes that provide reasonable assurance regarding the achievement of objectives related to operational efficiency, compliance, and asset security [1] Chapter 2: Audit Institutions and Personnel - The board of directors is responsible for establishing and implementing internal control systems, with significant internal control systems requiring board approval [2] - An audit committee is established by the board, consisting of directors, with independent directors making up more than half and at least one being a professional accountant [2][3] - The internal audit department is responsible for supervising the authenticity and completeness of financial information and internal control systems [2][3] Chapter 3: Responsibilities and General Requirements - The audit committee guides and supervises the internal audit department, reviews annual audit plans, and reports on audit progress and significant issues to the board [2][3] - The internal audit department evaluates the completeness and effectiveness of internal control systems across the company and its subsidiaries [3][4] Chapter 4: Specific Implementation - The internal audit department must conduct evaluations of internal controls at least annually and report findings to the audit committee [6][7] - Audits of significant external investments, asset purchases, guarantees, and related transactions must be conducted promptly, focusing on compliance with approval procedures and contract execution [8][9][10] Chapter 5: Violations and Responsibilities - Violations of laws, regulations, or internal policies may result in penalties, including administrative or economic sanctions for individuals involved in misconduct [10][12] Chapter 6: Supplementary Provisions - The internal audit system will be interpreted and revised by the board of directors and will take effect upon board approval [11]

北京佰仁医疗科技股份有限公司（以下简称"公司"）于 2025 年 8 月 27 日召开第三届董事会第十一次会议，审议通过了《关于取消公司监事会的议案》 《关于变更公司注册资本、修订 <公司章程> 并办理工商变更登记的议案》，同 日召开第三届监事会第八次会议，审议通过了《关于取消公司监事会的议案》。 现将有关情况说明如下： 证券代码：688198 证券简称：佰仁医疗 公告编号：2025-028 北京佰仁医疗科技股份有限公司 关于变更公司注册资本、取消监事会、修订《公司 章程》并办理工商变更登记的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、变更公司注册资本的情况 公司于 2025 年 6 月 13 日召开第三届董事会第十次会议、第三届监事会第 七次会议，审议通过了《关于公司 2020 年限制性股票激励计划首次授予部分第 五个归属期符合归属条件的议案》《关于公司 2020 年限制性股票激励计划预留 授予部分第三个归属期符合归属条件的议案》。2025 年 7 月 23 日，公司 2020 年 限制性股票激励计划首次授 ...

Core Points - The article outlines the information disclosure management system of Beijing Bairen Medical Technology Co., Ltd, aiming to enhance the quality of information disclosure and protect investors' rights [1][2][3] Group 1: General Principles - The company must disclose information truthfully, accurately, completely, and timely, avoiding any false records or misleading statements [2][3] - All investors should have equal access to significant information, and the company must not disclose information to select individuals or groups [2][3] - The company is required to establish an insider information management system to minimize the number of individuals privy to insider information before its public disclosure [2][3] Group 2: Disclosure Requirements - The company must disclose information that could significantly impact shareholders and stakeholders' decisions, ensuring that all shareholders have equal opportunities to access this information [2][3] - The content of announcements should be clear, concise, and free from excessive jargon or complex expressions [3][4] - The company must submit disclosure documents to the Shanghai Stock Exchange and publish them on designated media and websites [3][4] Group 3: Reporting Standards - The company is required to disclose significant information reflecting its business, technology, finance, governance, competitive advantages, industry trends, and risk factors [5][6] - Regular reports, including annual, semi-annual, and quarterly reports, must be disclosed within specified timeframes, ensuring that they contain all material information [9][10] - The company must disclose any major events that could affect its stock price or trading activities promptly [15][16] Group 4: Internal Management of Disclosure - The board of directors is responsible for overseeing the company's information disclosure, with the chairman being the final authority [27][28] - The board secretary is tasked with organizing and coordinating disclosure activities, ensuring compliance with regulations [27][28] - Senior management must ensure timely preparation and submission of reports for board review [28][29]

Core Points - The company, Beijing Bairen Medical Technology Co., Ltd., held its 11th meeting of the 3rd Board of Directors on August 27, 2025, where it approved the proposal to formulate and revise certain governance systems [1][2] - The revisions are in accordance with the current laws and regulations of the People's Republic of China, including the Company Law and Securities Law, aimed at promoting standardized operations within the company [1] - The specific governance systems being revised include the "Management System for Shares Held by Directors and Senior Management" and the "Rules for Shareholders' Meetings," with the latter being renamed [1] Governance System Changes - The company plans to revise several governance systems, specifically items 3 to 16 and item 25, which will be disclosed on the Shanghai Stock Exchange website simultaneously with this announcement [1]

Core Points - The document outlines the rules governing the behavior of the controlling shareholders and actual controllers of Beijing Bairen Medical Technology Co., Ltd, aiming to enhance corporate governance and ensure the company's healthy development [1][2][3] Group 1: General Principles - The rules are established to improve the corporate governance structure of the company and ensure its normal operation [1] - Controlling shareholders and actual controllers must comply with laws and regulations, exercising their rights without harming the interests of the company and other shareholders [2] - They are required to act in good faith, maintain the company's quality, and uphold the common interests of all shareholders [3] Group 2: Corporate Governance - Controlling shareholders and actual controllers must establish systems to clarify decision-making processes for significant matters and ensure the company's independence [5] - They should protect the integrity of the company's assets and not infringe upon the company's rights to its property [6] - They are prohibited from influencing the company's personnel independence and financial independence through improper means [9][10] Group 3: Information Disclosure - Controlling shareholders and actual controllers must fulfill their information disclosure obligations, ensuring that disclosed information is truthful, accurate, complete, and timely [6][7] - They must notify the company of significant events that could impact the company's securities trading prices [7][8] - They are required to maintain confidentiality regarding undisclosed significant information and not use it for personal gain [11][12] Group 4: Share Trading and Control Transfer - Controlling shareholders and actual controllers must adhere to legal regulations when trading company shares and must report any changes in shareholding that exceed specified thresholds [38][39] - They are prohibited from increasing their shareholding under certain conditions, such as during specific reporting periods [41] - Any transfer of control must be conducted fairly and without harming the interests of the company and other shareholders [42][43]

Core Viewpoint - The company is committed to enhancing operational quality, governance, and shareholder returns, aligning with national economic and financial directives to boost market confidence and support high-quality economic development [1]. Group 1: Business Focus and Product Development - The company is focusing on its core business by converting original research results into marketable products, thereby enhancing its core competitiveness [1]. - The company has received approval for its innovative transcatheter valve-in-valve product, which addresses the needs of patients with existing bioprosthetic valves, extending their durability [2]. - Multiple products, including eye biological patches and ePTFE materials, are progressing through the registration and clinical trial phases, ensuring a robust product pipeline for future growth [3]. Group 2: Shareholder Returns - The company has established a profit distribution plan for 2024, distributing a cash dividend of 0.80 yuan per share, totaling approximately 109.92 million yuan, which represents 75.12% of the net profit attributable to shareholders [4]. - The company has actively engaged in share buybacks, with the controlling shareholder increasing their stake by 124,759 shares, amounting to approximately 13.77 million yuan [5]. Group 3: Governance and Compliance - The company is enhancing its governance structure by revising internal policies and establishing new systems to ensure compliance and protect shareholder rights [6]. - The company has implemented a multi-level supervision mechanism for key personnel to ensure accountability and compliance with regulations [7]. Group 4: Investor Communication - The company has committed to transparent communication with investors, fulfilling its information disclosure obligations and ensuring the accuracy and timeliness of its reports [8]. - In the first half of 2025, the company released 27 reports and held performance briefings to engage with investors and convey its value proposition [8].